← Back to Search

Nonsteroidal Anti-inflammatory Drug

Salsalate Oral Tablet for Prophylaxis of Preeclampsia

Q: What is the current cohort size for this research project?

Indeed, the clinicaltrials.gov website denotes that this research endeavor is actively seeking recruits. This trial was initially posted on August 26th 2018 and its information has been revised most recently on May 16th 2022. The recruitment drive aims to enlist 32 participants at 2 distinct sites.

Q: Can you describe any additional investigations that include Salsalate Oral Tablet?

Currently, 5 clinical trials are examining Salsalate Oral Tablet. One of these research projects is in its final phase. While the majority of the studies based in Ann Arbor, <a href="https://www.withpower.com/clinical-trials/michigan">Michigan</a>, a total 10 sites are conducting investigations for this medication.

Q: Is enrollment for this research endeavor presently accessible to participants?

According to the information on clinicaltrials.gov, this trial is actively recruiting patients. The study was initially advertised in August of 2018 and it's most recent update occurred on May 16th 2022.

Phase < 1

Recruiting

Led By Anna Stanhewicz, PhD

Research Sponsored by University of Iowa

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up a total of 3 times throughout the study (approximately 4 weeks): 1) at the beginning of the study, 2) at the completion of the 5 day placebo treatment, and 3) at the completion of 5 days of oral salsalate treatment

Awards & highlights

Study Summary

This trial is investigating why women who develop preeclampsia during pregnancy are more likely to develop cardiovascular disease later in life, in order to identify better clinical management of cardiovascular disease risk in these women.

Eligible Conditions

Prophylaxis of Preeclampsia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ a total of 3 times throughout the study (approximately 4 weeks): 1) at the beginning of the study, 2) at the completion of the 5 day placebo treatment, and 3) at the completion of 5 days of oral salsalate treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~a total of 3 times throughout the study (approximately 4 weeks): 1) at the beginning of the study, 2) at the completion of the 5 day placebo treatment, and 3) at the completion of 5 days of oral salsalate treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and a total of 3 times throughout the study (approximately 4 weeks): 1) at the beginning of the study, 2) at the completion of the 5 day placebo treatment, and 3) at the completion of 5 days of oral salsalate treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

change in endothelial function following salsalate treatment compared to placebo treatment

Secondary outcome measures

change in inflammatory response to ang II compared to baseline

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: SalsalateExperimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Penn State UniversityOTHER

355 Previous Clinical Trials

125,725 Total Patients Enrolled

University of IowaLead Sponsor

446 Previous Clinical Trials

879,470 Total Patients Enrolled

Anna Stanhewicz, PhDPrincipal Investigator - University of Iowa

University of Iowa

3 Previous Clinical Trials

74 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current cohort size for this research project?

"Indeed, the clinicaltrials.gov website denotes that this research endeavor is actively seeking recruits. This trial was initially posted on August 26th 2018 and its information has been revised most recently on May 16th 2022. The recruitment drive aims to enlist 32 participants at 2 distinct sites."

Answered by AI

Can you describe any additional investigations that include Salsalate Oral Tablet?

"Currently, 5 clinical trials are examining Salsalate Oral Tablet. One of these research projects is in its final phase. While the majority of the studies based in Ann Arbor, Michigan, a total 10 sites are conducting investigations for this medication."

Answered by AI

Is enrollment for this research endeavor presently accessible to participants?

"According to the information on clinicaltrials.gov, this trial is actively recruiting patients. The study was initially advertised in August of 2018 and it's most recent update occurred on May 16th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia

Anna Stanhewicz, PhD 2018. "Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03482440.

All > Preeclampsia